Medical · Medium Term trend · Travel

Medical tourism : Medium term trend

Health · Long term trend · Medical

Healthcare Spending : Long term !!

Medical

Global Orthopaedic Market

Medical · Pharma

Innovator CDMO market

Long term trend · Medical

AI enabled Medical Devices : Long term Trend

Medical

Refurbished medical devices : no Athithi Devoh Bhavah

Medical · Pharma

CRDMO : Getting pace on growth

Medical · Stocks

Forehead lines

Medical

Foreign Medical tourism : India

Foreign Medical tourism : India
Medical · Pharma

Pharmacy Density

Diabetes · Keto Diet · Long term trend · Medical

OVER(Weight)

Medical · Pharma

qPCR to dPCR

image

Medical

Medical Devices

Health · Medical · Pharma · Technology

AI in Healthcare

Medical

Indian Dental industry

Indian Dental industry
Medical

Hospitals Business : Best (Max) Performance

Life · Medical · Stocks · Technology

Ael : we are only 50!!

Businessline
Medical

Growing Market

Medical · Medicine · Medium Term trend

E-pharmacy vs retail

Source : Frost and Sullivan report
Medical · Stocks

Medical devices : Aatmnirbhar Version

IPO · Medical · Stocks

Vijay Diagnostics IPO : Subscribe or NOT?

The data has been compiled from various sources and might have small difference but overall theme is to subscribe or not — we will focus on that

Vijay Diagnostic Center IPO-Established in 1981, Vijaya Diagnostic Centre is one of the fastest-growing diagnostic chains in Southern India

Business — The company offers a one-stop solution for pathology and radiology testing services. The company offers around 740 routine tests, 870 specialized pathology tests, 220 basic tests, and 320 advanced radiology tests. The company also offers a broad spectrum of customized health and wellness packages to its customers.

Region of operation — Company’s operational network consists of 80 diagnostic centers and 11 reference laboratories spread across 13 cities and towns in the states of Telangana, Andhra Pradesh, National Capital Region, and Kolkata. 96.2% of the revenue comes from Hyderabad, the rest of Telangana, and the Andhra Pradesh region.

Offer purpose —  

The IPO is entirely an offer for sale to provide partial exit to existing investors, who will be divesting 30 per cent of the stake

while the promoter is divesting 5 per cent.

Risks

Company is in a highly competitive space

High regional concentration risk

Company not getting any proceeds from IPO for growth

Strength

Largest and fastest-growing diagnostic chain in Southern India.

Affordable diagnostics service provider with a focus on superior quality.

Strong technical capabilities, cutting-edge diagnostic testing technology and robust IT infrastructure.

High brand recalls driving high individual consumer business.

Future

Company is operating with non-franchise model so growth is based on company reach. Focus is more on quality which bring people back to same place. Although the industry is highly competitive, but regional it has strong presence.

Valuations

Valuations are slightly lower considering peers but look reasonable

If we see growth projections, then valuations are at par or premium only

Should we apply?

We can completely avoid

Wait for lower prices to emerge to invest

In case you have any questions/ queries, please feel free to reach me through Contact Form

Do spread the word among your peers, family members or anyone who can benefit from this blog and asked them to subscribe. But be selfish and take care of yourself first by subscribing before they do.

Enjoy the day and your life. Don’t forget, we are alone in this grand universe and may not get a chance to live again.

Health · IPO · Medical · Stocks

Clean Science and Technology IPO : Subscribe or NOT?

The data has been compiled from various sources and might have small difference but overall theme is to subscribe or not — we will focus on that

Clean Science and technology IPO– Incorporated in the year 2003, fine and specialty chemical manufacturing company, with innovative chemical processes developed in-house. Clean Science and Technology is a family-owned business and work primarily on developing clean and eco-friendly manufacturing processes.

Business — Clean Science Technology manufactures functionally critical specialty chemicals such as performance chemicals, pharmaceutical intermediates and FMCG chemicals. Its products are used as key starting level materials, as inhibitors, or as additives, by customers, for products

Region of operation — Customers include manufacturers and distributors in India as well as other international markets including China,
Europe, the US, Taiwan, Korea, and Japan. Approx. 66% of the company’s revenues come from exports

Offer purpose —  The IPO is 100% Offer For Sale (OFS) . None of the proceeds will flow to the company

Risks

Company will not get anything from IPO for future expansion etc

Highly competitive industry and well established peers

High dependence on exports

Strength

Globally leading supplier of certain chemicals; Ansole, 4-MAP, MEHQ, BHA, DCC, etc.

Strategically located manufacturing facility with close proximity to JNPT port to export products.

Strong long-term relationship with key customers.

Consistent track record of financial performance.

International presence with export to several countries i.e. China, USA, Korea, Japan, Taiwan, etc.

Future

Company has been growing well and automated operations, continued focus on product identification, process innovation, catalyst development, significant scale of operations as well as our measures towards strategic backward integration have all contributed to its success as one of the fastest growing and among the most profitable specialty chemical companies globally .

Valuations

Valuations are little on higher side and compare well with peers

Should we apply?

People can subscribe for long term and keep on adding on dips & review holdings with each quarter earnings

Also Read

Burger King IPO crisp Summary — Listing with huge gains as shared

CAMS IPO crisp summary — Listed with 20% gains as shared

Happiest Minds IPO crisp summary –Listed with substantial gains as shared

In case you have any questions/ queries, please feel free to reach me through Contact Form

Do spread the word among your peers, family members or anyone who can benefit from this blog and asked them to subscribe. But be selfish and take care of yourself first by subscribing before they do.

Enjoy the day and your life. Don’t forget, we are alone in this grand universe and may not get a chance to live again.

Health · IPO · Medical · Stocks

KIMS IPO : Subscribe or NOT?

The data has been compiled from various sources and might have small difference but overall theme is to subscribe or not — we will focus on that

KIMS IPO– Incorporated in the year 1973, KIMS is one of the largest corporate healthcare groups in Andhra Pradesh and Telangana in terms of patients treated and treatments offered.

Business — The Hyderabad-based hospital chain offers multidisciplinary healthcare services with primary, secondary, and tertiary care across 2-3 tier cities, and an additional quaternary healthcare facility in tier-1 cities. 

Region of operation –Main presence in 2 states , Telagana and Andhra Pradesh

Offer purpose —  The IPO includes a fresh issue of Rs 200 cr and an Offer For Sale (OFS) of up to 2.35 cr equity shares by the promoters and existing shareholders. This includes roughly 1.6 cr shares by the biggest investor in the company – General Atlantic Singapore KH Pte. for prepayment of borrowings and general purposes

Risks

Extremely high level of dependency on top 10 doctors

Concentrated region of operation

ARPOB is on the lower side as compared to industry numbers

Strength

Multidisciplinary healthcare services with primary, secondary, and tertiary care across 2-3 tier cities at afforable rates

Better cost operating profile wrt peers due to operational leverage

Strong Balance sheet and operating margins

KIMS has expanded its business by successfully completing 4 significant acquisitions from FY 2017-2018 to FY 2019-2020 

Future

Company has plans to expand number of beds and expanding in Chennai and Bengaluru in coming years that will help the growth

As hospital chain becomes more mature, EBITDA margin will improve further

Valuations

Valuations are reasonable and compare well with peers

Source Business Line

Should we apply?

People can subscribe for long term and keep on adding on dips & review holdings with each quarter earnings

Also Read

Burger King IPO crisp Summary — Listing with huge gains as shared

CAMS IPO crisp summary — Listed with 20% gains as shared

Happiest Minds IPO crisp summary –Listed with substantial gains as shared

In case you have any questions/ queries, please feel free to reach me through Contact Form

Do spread the word among your peers, family members or anyone who can benefit from this blog and asked them to subscribe. But be selfish and take care of yourself first by subscribing before they do.

Enjoy the day and your life. Don’t forget, we are alone in this grand universe and may not get a chance to live again.

Medical · Medicine

Monopoly looks like this

MONOPOLY LOOKS LIKE THIS : Schott AG vials
Source Business line

Medical · Stocks

ThermoFisher Scientific : CoviPath RT-PCR

THERMOFISHER SCIENTIFIC : COVIPATH RT-PCR
Business Line
Health · Medical

Aatmnirnbhar Version : PLI : Medical Devices